Famotidine and Antacids for Treatment of Dyspepsia
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18+
SponsorStony Brook University
About this trial
The aim of this study is to compare intravenous famotidine, an H2 receptor antagonist, and Maalox/ Mylanta, an oral antacid, in treatment of dyspepsia in the emergency department. The goal of this study is to reduce patients' pain based on the verbal numerical pain scale. The anticipated outcome is for pain levels in both groups to decrease. It is expected that antacids will improve symptoms more quickly and to a greater degree within an hour of taking medication based on the results of similar studies.
Eligibility criteria
Qualifiers
Subject Age ≥ 18 years of age
Patient diagnosed with dyspepsia
Present at the ED with upper abdominal pain score of at least 3
Disqualifiers
Hypersensitivity to an ingredient in Maalox/ Mylanta or Famotidine
Moderate to Severe Renal Insufficiency (precaution)
Kidney Failure
Pregnant or Nursing
Trial design
Treatments tested in this trial
- Intravenous Famotidine
- Oral Maalox/ Mylanta
Treatment groups
80 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov